M&G Plc Acquires 21,251 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

M&G Plc raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 26.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,536 shares of the medical equipment provider’s stock after purchasing an additional 21,251 shares during the quarter. M&G Plc’s holdings in Zimmer Biomet were worth $10,858,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ZBH. BLB&B Advisors LLC increased its holdings in Zimmer Biomet by 2.1% during the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after buying an additional 100 shares during the last quarter. Financial Advocates Investment Management grew its position in shares of Zimmer Biomet by 3.5% during the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after acquiring an additional 103 shares during the period. PFG Advisors increased its stake in shares of Zimmer Biomet by 5.5% during the 1st quarter. PFG Advisors now owns 2,004 shares of the medical equipment provider’s stock worth $265,000 after purchasing an additional 105 shares during the last quarter. M&R Capital Management Inc. raised its holdings in shares of Zimmer Biomet by 14.1% in the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 105 shares during the period. Finally, Mill Creek Capital Advisors LLC lifted its stake in Zimmer Biomet by 5.1% in the second quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 106 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Down 1.3 %

ZBH opened at $108.69 on Friday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The business’s fifty day simple moving average is $106.64 and its 200 day simple moving average is $110.58. Zimmer Biomet Holdings, Inc. has a 52 week low of $101.47 and a 52 week high of $133.90. The stock has a market cap of $21.64 billion, a PE ratio of 20.66, a P/E/G ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $1.65 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wolfe Research started coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, September 10th. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, September 16th. Raymond James lowered their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Finally, Wells Fargo & Company raised their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.